title: New targeted therapies in pituitary carcinoma resistant to temozolomide.
abstract: To evaluate the antitumoral efficacy of everolimus in pituitary carcinoma resistant to temozolomide, the correlation with mammalian target of rapamycin (mTOR) signaling in the tumor and to present recent advances and future treatments of pituitary carcinomas. Pituitary carcinomas are rare and largely unresponsive to current treatment options. Recent reports on the antitumoral efficacy of temozolomide in some such patients are encouraging, yet most patients appear to show resistance to its actions. As a potential alternative, the mTOR inhibitor, everolimus, has been shown to potently inhibit pituitary cell proliferation highlighting mTOR inhibition as a promising therapeutic approach for pituitary carcinomas. We described the tumoral effects of a combination therapy with everolimus (5 mg/day) and octreotide (30 mg/month) and the mTOR signalling expression in a patient with pituitary ACTH carcinoma, compared to 17 other ACTH adenomas. Clinical and biochemical evaluation were performed every month, and imaging after 3 month of treatment. mTOR signaling was assessed by microarray expression analysis of each of the 18 adenoma tissues. Combined therapy failed to control pituitary tumor growth and ACTH secretion. Slight activation of mTOR signaling was found in all ACTH tumors alongside important variations between tumors. Low antitumor efficacy shown by everolimus might be explained by the weak activation of mTOR pathway in ACTH tumors. Everolimus treatment was inefficient at controlling secretion and tumor growth of one ACTH pituitary carcinoma. More clinical cases, with mTOR signalling expression analysis of the tumor, must be published before any conclusions can be drawn.
authors.affiliation: INSERM, U1028/CNRS, UMR5292. Lyon Neuroscience Research Center, Neuro-Oncology and Neuro-inflammation Team, 69000, Lyon, France.
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Jouanneau
authors.forename: Anne
authors.initials: A
authors.lastname: Wierinckx
authors.forename: François
authors.initials: F
authors.lastname: Ducray
authors.forename: Véronique
authors.initials: V
authors.lastname: Favrel
authors.forename: Françoise
authors.initials: F
authors.lastname: Borson-Chazot
authors.forename: Jérôme
authors.initials: J
authors.lastname: Honnorat
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Trouillas
authors.forename: Gérald
authors.initials: G
authors.lastname: Raverot
mesh_terms: D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D000068338:Everolimus; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077204:Temozolomide
chemical_list: D003606:Dacarbazine; D000068338:Everolimus; D020123:Sirolimus; D000077204:Temozolomide